| Regional differences in antithrombotic treatment for atrial fibrillation: insights from the GLORIA-AF Phase II Registry M Mazurek, MV Huisman, KJ Rothman, M Paquette, C Teutsch, ... Thrombosis and haemostasis 117 (12), 2376-2388, 2017 | 104 | 2017 |
| Two-year follow-up of patients treated with dabigatran for stroke prevention in atrial fibrillation: Global Registry on Long-Term Antithrombotic Treatment in Patients with … MV Huisman, KJ Rothman, M Paquette, C Teutsch, HC Diener, SJ Dubner, ... American Heart Journal 198, 55-63, 2018 | 59 | 2018 |
| Persistence with dabigatran therapy at 2 years in patients with atrial fibrillation M Paquette, L Riou França, C Teutsch, HC Diener, S Lu, SJ Dubner, ... Journal of the American College of Cardiology 70 (13), 1573-1583, 2017 | 52 | 2017 |
| Stroke‐prevention strategies in North American patients with atrial fibrillation: The GLORIA‐AF registry program WF McIntyre, D Conen, B Olshansky, JL Halperin, E Hayek, MV Huisman, ... Clinical cardiology 41 (6), 744-751, 2018 | 34 | 2018 |
| Gender differences in antithrombotic treatment for newly diagnosed atrial fibrillation: the GLORIA-AF registry program M Mazurek, MV Huisman, KJ Rothman, M Paquette, C Teutsch, ... The American Journal of Medicine 131 (8), 945-955. e3, 2018 | 33 | 2018 |
| Dabigatran persistence and outcomes following discontinuation in atrial fibrillation patients from the GLORIA-AF registry M Paquette, LR França, C Teutsch, HC Diener, S Lu, SJ Dubner, CS Ma, ... The American Journal of Cardiology 125 (3), 383-391, 2020 | 31 | 2020 |
| Antithrombotic treatment for newly diagnosed atrial fibrillation in relation to patient age: the GLORIA-AF registry programme M Mazurek, JL Halperin, MV Huisman, HC Diener, SJ Dubner, CS Ma, ... EP Europace 22 (1), 47-57, 2020 | 27 | 2020 |
| Changes in anticoagulant prescription patterns over time for patients with atrial fibrillation around the world M Kozieł, C Teutsch, V Bayer, S Lu, VK Gurusamy, JL Halperin, ... Journal of arrhythmia 37 (4), 990-1006, 2021 | 26 | 2021 |
| Safety and effectiveness of dabigatran at 2 years: final outcomes from phase II of the GLORIA-AF registry program M Mazurek, C Teutsch, HC Diener, SJ Dubner, JL Halperin, CS Ma, ... American heart journal 218, 123-127, 2019 | 23 | 2019 |
| Persistence with anticoagulation for atrial fibrillation: report from the GLORIA-AF phase III 1-year follow-up M Kozieł, M Mazurek, C Teutsch, HC Diener, SJ Dubner, JL Halperin, ... Journal of Clinical Medicine 9 (6), 1969, 2020 | 17 | 2020 |
| Dabigatran versus vitamin K antagonists for atrial fibrillation in clinical practice: final outcomes from Phase III of the GLORIA-AF registry MV Huisman, C Teutsch, S Lu, HC Diener, SJ Dubner, JL Halperin, ... Clinical Research in Cardiology 111 (5), 548-559, 2022 | 16 | 2022 |
| Atrial fibrillation and comorbidities: Clinical characteristics and antithrombotic treatment in GLORIA-AF M Kozieł, C Teutsch, JL Halperin, KJ Rothman, HC Diener, CS Ma, ... PloS one 16 (4), e0249524, 2021 | 11 | 2021 |
| Stroke prevention in atrial fibrillation changes after dabigatran availability in China: the GLORIA‐AF registry C Ma, L Riou França, S Lu, HC Diener, SJ Dubner, JL Halperin, Q Li, ... Journal of Arrhythmia 36 (3), 408-416, 2020 | 11 | 2020 |
| Influence of BMI and geographical region on prescription of oral anticoagulants in newly diagnosed atrial fibrillation: the GLORIA-AF Registry Program G Boriani, MV Huisman, C Teutsch, S Marler, LR França, S Lu, GYH Lip, ... European Journal of Internal Medicine 80, 35-44, 2020 | 9 | 2020 |
| Characteristics and 2‐year outcomes of dabigatran treatment in patients with heart failure and atrial fibrillation: GLORIA‐AF SJ Dubner, C Teutsch, MV Huisman, HC Diener, J Halperin, KJ Rothman, ... ESC Heart Failure 7 (5), 2679-2689, 2020 | 8 | 2020 |
| Evolution of antithrombotic therapy for patients with atrial fibrillation: The prospective global GLORIA-AF registry program L Beier, S Lu, LR França, S Marler, GYH Lip, MV Huisman, C Teutsch, ... PloS one 17 (10), e0274237, 2022 | 5 | 2022 |
| GLORIAAF Investi‑gators. Two‑year follow‑up of patients treated with dabigatran for stroke preven‑tion in atrial fibrillation: Global Registry on Long‑Term Antithrombotic … MV Huisman, KJ Rothman, M Paquette, C Teutsch, HC Diener, SJ Dubner, ... Am Heart J 198, 55-63, 2018 | 5 | 2018 |
| Predictors of anticoagulant prescription in patients with atrial fibrillation in North America: the GLORIA-AF Registry WF McIntyre, D Conen, B Olshansky, J Halperin, E Hayek, M Huisman, ... Journal of the American College of Cardiology 69 (11S), 413-413, 2017 | 3 | 2017 |
| Anticoagulation prescription and outcomes in relation to renal function in patients with atrial fibrillation: results from GLORIA-AF SJ van der Wall, C Teutsch, SJ Dubner, HC Diener, JL Halperin, CS Ma, ... TH Open 5 (01), e35-e42, 2021 | 2 | 2021 |
| P2887 Two-year outcomes of dabigatran etexilate treatment in patients with co-morbid heart failure and atrial fibrillation: the GLORIA-AF registry SJ Dubner, MV Huisman, HC Diener, JL Halperin, KJ Rothman, CS Ma, ... European Heart Journal 39 (suppl_1), ehy565. P2887, 2018 | 1 | 2018 |
